225 related articles for article (PubMed ID: 18817994)
1. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
[TBL] [Abstract][Full Text] [Related]
2. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trials with levosimendan.
Mebazaa A; Barraud D; Welschbillig S
Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
[TBL] [Abstract][Full Text] [Related]
4. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
5. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies.
Landoni G; Biondi-Zoccai G; Greco M; Greco T; Bignami E; Morelli A; Guarracino F; Zangrillo A
Crit Care Med; 2012 Feb; 40(2):634-46. PubMed ID: 21963578
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies.
Landoni G; Mizzi A; Biondi-Zoccai G; Bignami E; Prati P; Ajello V; Marino G; Guarracino F; Zangrillo A
Minerva Anestesiol; 2010 Apr; 76(4):276-86. PubMed ID: 20332741
[TBL] [Abstract][Full Text] [Related]
7. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
8. Is there a place for levosimendan in the intensive care unit?
Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
Crit Care Resusc; 2007 Sep; 9(3):290-2. PubMed ID: 17767458
[TBL] [Abstract][Full Text] [Related]
9. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
Gong B; Li Z; Yat Wong PC
J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1415-25. PubMed ID: 26275522
[TBL] [Abstract][Full Text] [Related]
10. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Nieminen MS; Sandell EP
Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan compared with dobutamine in low output patients.
Nieminen MS
Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
14. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
15. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan: current status and future prospects.
Archan S; Toller W
Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
20. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
